CoChat

Safety and efficacy of saxagliptin for glycemic control in non-critically ill hospitalized patients

Open access
Garg, Rajesh, Schuman, Brooke, Hurwitz, Shelley, Metzger, Cheyenne, Bhandari, Shreya · 2017 · BMJ Open Diabetes Research & Care

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

Objective: To evaluate whether saxagliptin is non-inferior to basal-bolus insulin therapy for glycemic control in patients with controlled type 2 diabetes mellitus (T2DM) admitted to hospital with non-critical illnesses. Research design and methods: This was an open-label, randomized controlled clinical trial. Patients received either saxagliptin or basal-bolus insulin, both with correctional insulin doses. The main study outcome was the mean daily blood glucose (BG) after the first day of randomization. Results: Of 66 patients completing the study, 33 (age 69±10 years, 40% men) were randomized to saxagliptin and 33 (age 67±10 years, 52% men) to basal-bolus insulin therapy. The mean daily BG was 149.8±22.0 mg/dL in the saxagliptin group and 146.9±30.5 mg/dL in the insulin group (p=0.59). With an observed group difference of 2.9 mg/dL and an a priori margin of 20 mg/dL, inferiority of saxagliptin was rejected in favor of non-inferiority (p=0.007). There was no significant difference in the percentage of high or low BG values. The insulin group received a higher number of insulin injections (2.3±1.7/day vs 1.2±1.9/day; p<0.001) as well as a higher daily insulin dose (13.3±12.9 units/day vs 2.4±3.3 units/day; p<0.001) than did the saxagliptin group. Continuous BG monitoring showed that glycemic variability was lower in the saxagliptin group as compared to the insulin group. Patient satisfaction scores were similar in the two groups. Conclusions: We conclude that saxagliptin use is non-inferior to basal-bolus insulin in non-critically ill hospitalized patients with T2DM controlled on 0–2 oral agents without insulin. Saxagliptin use may decrease glycemic variability in these patients. Trial registration number: NCT02182895.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjdrc-2017-000394

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Patient flow through the study.
Figure 1 Patient flow through the study.CC BY-NC · PubMed Central
Figure 2 Mean blood glucose levels and insulin use during the course of the study.
Figure 2 Mean blood glucose levels and insulin use during the course of the study.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Research works printed but not linked: 1

  1. 10.1210/jc.87.3.978 · DOI · Paper page

Cited by

See all 79

Metadata

Authors
Garg, R., Schuman, B., Hurwitz, S., Metzger, C., & Bhandari, S.
Affiliations
Brigham and Women's Hospital (US)
Corresponding author
Garg, Rajesh
Venue
BMJ Open Diabetes Research & Care
Publisher
BMJ
Published
2017-03
Volume
5
Issue
1
Pages
e000394
ISSN
2052-4897 (ISSN-L)
OpenAlex
W2599515436
Cited by
79
References
24
Citations by year
2026: 1 · 2025: 3 · 2024: 8 · 2023: 8 · 2022: 11 · 2021: 12 · 2020: 12 · 2019: 11 · 2018: 10 · 2017: 3
FWCI
7.79
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • BMJ Open Diabetes Research & Care (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
Funders
AstraZeneca
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
saxagliptin, multiple daily insulin injections, type 2 diabetes, glycemic control, hospitalized patients, non-critically ill patients, glycemic variability, continuous glucose monitoring, non-inferiority, insulin dose reduction, patient satisfaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and efficacy of saxagliptin for glycemic control in non-critically ill hospitalized patients. https://app.cochat.ai/papers/10.1136/bmjdrc-2017-000394
The paper
Garg, R., Schuman, B., Hurwitz, S., Metzger, C., & Bhandari, S. (2017). Safety and efficacy of saxagliptin for glycemic control in non-critically ill hospitalized patients. BMJ Open Diabetes Research & Care. https://doi.org/10.1136/bmjdrc-2017-000394

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.